• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,867.84
  • 0.18 %
  • $73.23
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,162.39
  • -0.27 %
  • -$21.85
  • IXIC
  • $18,294.80
  • 0.63 %
  • $114.81
Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News & Analysis

Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News & Analysis

Currency in USD Disclaimer

$19.23

$0.29

(1.53%)

Day's range
$19.1
Day's range
$19.27
50-day range
$17.34
Day's range
$21.56
  • Country: US
  • ISIN: US87164F1057
52 wk range
$13.14
Day's range
$25.34
  • CEO: Mr. Michael A. Metzger M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 18.70
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (SNDX)
  • Company Syndax Pharmaceuticals, Inc.
  • Price $19.23
  • Changes Percentage (1.53%)
  • Change $0.29
  • Day Low $19.10
  • Day High $19.27
  • Year High $25.34

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/04/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $37.00
  • High Stock Price Target $41.00
  • Low Stock Price Target $31.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.24
  • Trailing P/E Ratio -6.02
  • Forward P/E Ratio -6.02
  • P/E Growth -6.02
  • Net Income $-209,360,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.